24/7 Market News Snapshot 11 June, 2025 – Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS)

June 11, 2025

DENVER, Colo., 11 June, 2025 (www.247marketnews.com) – (Nasdaq:INTS) are discussed in this article.
Intensity Therapeutics, Inc. (Nasdaq:INTS) has recently reported promising preliminary results from its Phase 2 INVINCIBLE-4 clinical study, which evaluates the efficacy of INT230-6 in patients with operable triple-negative breast cancer (TNBC). The study, designed as a randomized, open-label trial, aims to compare the treatment regimen involving INT230-6 followed by standard neoadjuvant immunochemotherapy against the standard regimen alone. Notably, initial data indicates significant tumor necrosis within just eight days of INT230-6 treatment, prior to beginning the conventional treatment phase. A primary endpoint of the study is focused on achieving a pathological complete response (pCR).

Dr. Ursina Zürrer, who is the Chief Physician and Coordinating Investigator, expressed optimism regarding these results, highlighting the promising levels of tumor necrosis observed in the initial MRI scans. This early efficacy indicates the potential of INT230-6 to elicit a robust anti-tumor response ahead of standard treatment, which could significantly improve patient outcomes.

The formulation of INT230-6 incorporates clinically validated agents, cisplatin and vinblastine sulfate, along with an innovative enhancer designed to improve drug distribution within tumors. This dual approach aims to not only attack cancer cells directly but also enhance immune recognition of the tumors, recognizing a significant unmet need in current TNBC therapies.

In addition to the clinical advancements, Intensity Therapeutics has experienced a notable market reaction as its stock opened at $0.493 and surged to $0.575, a 14.31% increase from the previous close of $0.503. With a trading volume of 5.01 million shares, the stock’s performance reflects growing investor interest. Observers are keenly monitoring resistance levels around $0.58, which may provide insight into future price movements amid heightened market activity. Lewis H. Bender, President and CEO of Intensity Therapeutics, emphasized the company’s commitment to innovating cancer therapies and the excitement surrounding the potential for improved pCR rates in this challenging therapeutic area.

Related news for (INTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.